Novartis may be planning to sell off its generics business Sandoz, but that hasn't stopped it investing in the unit ahead of a decision on its future later this year.
Mallinckrodt's liability problems in the US have been lightened slightly, after it agreed a $260 million deal to resolve allegations of Medicare rebate fraud and payment of illegal kickback
Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales
As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going conc
Purdue Pharma and its controlling Sackler family have offered a new settlement to resolve lawsuits over their involvement in the opioid epidemic, raising the payout from the Sacklers to $6
Novo Nordisk's rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates it will help drive obesity sales
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.